Use of an Aromatase Inhibitor for Induction of Ovulation in Patients With an Inadequate Response to Clomiphene Citrate

Comparison of the efficacy of the aromatase inhibitor letrozole and clomiphen citrate gonadotropins in controlled ovarian hyperstimulation: a prospective, simply randomized, clinical trial

“…This finding is in line with the results obtained by Mitwally et al [20] and Sohrabvand et al [21]. It is probable that the cause of endometrial thickening in patients receiving letrozole is because of improved vascularization as compared with clomiphene citrate [22].Another study also showed that clomiphene citrate can cause inadequate endometrial thickness in 15-50% of patients and have negative effects on the quality or quality of the cervical and endometrial mucosa [22].These complications may be attributed to the anti-estrogenic effect and the relatively longer half-life of clomiphene citrate [11].…”

“…Because of its long half-life (2 weeks), cc accumulates in the body and may have a negative effect on the quality and quantity of cervical mucus, endometrial development, which may cause implantation failure, luteal phase defects and significant thinning of the endometrium, which is dose dependent [8][9][10].These adverse effects of cc on the endometrium may explain in part the relatively poor pregnancy rates associated with cc despite the high rate of ovulation. Recently, aromatase inhibitor has been investigated as a potential ovulation induction agent [11].Because it does not deplete estrogen receptors in central and peripheral target tissues, it typically results in mono-ovulation and it may have no negative impact on endometrium and cervical mucus [12][13].The aromatase inhibitors have a relatively short half-life (45 h) [14] compared with CC and therefore would be eliminated from the body rapidly [15].…”

Ovarfunktionsstörungen

“…Zyklustag mit 2,5 mg täglich eingesetzt. Die Ovulationsraten und Schwangerschaftsraten sind mindestens so gut wie bei der Clomifen-Therapie [9].…”

Aromatasehemmer in der Therapie der Endometriose

“…AH steigern das Follikelwachstum und können zu einer Ovarstimulation und Zystenbildung führen [21]. Da AH zu einer FSH-Sekretion in der Hypophyse füh-ren, wurden AH der 3.…”